利舒康胶囊对支气管哮喘患者慢性缺氧的治疗疗效探讨  

Discussion on efficacy of Lishukang capsule on chronic hypoxia in patients with bronchial asthma

作　　者：刘仕杰[1] 徐向东 LIU Shi-jie;XU Xiang-dong(Department of Emergency, Shandong Yantai Laiyang Central Hospital, Yantai 265200, China)

机构地区：[1]烟台市莱阳中心医院急诊科,265200 [2]不详

出　　处：《中国实用医药》2018年第36期115-117,共3页China Practical Medicine

摘　　要：目的探讨抗高原缺氧性药物利舒康胶囊对支气管哮喘患者慢性缺氧的临床疗效。方法选取85例支气管哮喘发作患者,随机分为治疗组(42例)和对照组(43例)。对照组给予常规抗支气管哮喘药物(平喘、抗炎性介质、氧疗等),治疗组在对照组治疗基础上加用利舒康胶囊。治疗4周后观察两组患者慢性缺氧指标[血红蛋白(HGB)、红细胞压积(Hct)、同型半胱氨酸(Hcy)、乳酸(Lac)、及动脉血氧分压(PaO_2)]的变化情况。结果治疗4周后,随访两组患者均未再复发,临床慢性缺氧症状均好转,两组HGB、Hct、Hcy及Lac均明显低于治疗前,且PaO_2均明显高于治疗前,差异均有统计学意义(P<0.05)。治疗组治疗4周后的HGB、Hct、Hcy及Lac均明显低于对照组,且PaO_2均明显高于对照组,差异均有统计学意义(P<0.05)。结论抗高原缺氧性药物利舒康胶囊可明显改善支气管哮喘患者慢性缺氧及相应机体功能下降的情况,临床疗效确切,值得推广应用。Objective To discuss the clinical efficacy of Lishukang capsule on chronic hypoxia in patients with bronchial asthma. Methods A total of 85 patients with bronchial asthma were randomly divided into treatment group (42 cases)and control group (43 cases). The control group received conventional anti-bronchial asthma drugs (asthma, anti-inflammatory mediators, oxygen therapy), and the treatment group received Lishukang capsule on the control group. After 4 weeks of treatment, the changes of chronic hypoxia indexes[ hemoglobin (HGB), hematocrit (Hct), homocysteine (Hcy), lactic acid (Lac), and arterial partial pressure of oxygen (PaO2)] between the two groups were observed. Results After 4 weeks of treatment, no recurrence was found in the two groups and the symptoms of chronic hypoxia were improved. Both groups had obviously lower HGB, Hct, Hcy and Lac than those before treatment, and obviously higher PaO2 than those before treatment. The differences were statistically significant (P<0.05). Both groups had obviously lower HGB, Hct, Hcy and Lac than those before treatment, and obviously higher PaO2 than those before treatment. The differences were statistically significant (P<0.05). After 4 weeks of treatment, the treatment group had obviously lower HGB, Hct, Hcy and Lac than the control group, and obviously higher PaO2 than the control group. The differences were statistically significant (P<0.05). Conclusion Lishukang capsule, an anti-altitude hypoxia drug, can significantly improve the chronic hypoxia and the decline of the corresponding body function in patients with bronchial asthma. It has a definite clinical effect and is worth popularizing and applying.

关 键 词：利舒康胶囊 支气管哮喘 缺氧 

分 类 号：R562.25[医药卫生—呼吸系统]